文献速递角膜与眼表疾病白内障与屈光手术

局部雌激素滴眼液用于远视矫正的体内研究

Topical Estrogen Therapy for Hyperopia Correction in Vivo.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

研究使用12只16周龄雌性新西兰白兔,随机分为1.5%雌激素滴眼液组和溶媒对照组,右眼每12小时给药一次共35天。结果显示两组均出现角膜变平和远视漂移,但治疗组变化速率较慢,角膜曲率读数组间差异有统计学意义(P=0.034),治疗组角膜曲率最多陡峭0.6屈光度,停药后差异消失。

要点

  • 局部1.5%雌激素滴眼液使兔眼角膜曲率读数更陡,产生近视漂移。
  • 角膜曲率组间差异有统计学意义(P=0.034),最大差异达0.6屈光度。
  • 停药后组间差异减小并失去统计学意义,眼压和角膜厚度无显著变化。

核心结论

  • 雌激素滴眼液诱导了角膜曲率读数的近视漂移,提示角膜屈光力可能通过药物调控。

研究设计与样本

  • 研究使用12只16周龄雌性新西兰白兔,随机分为1.5%(w/v)雌激素滴眼液组和溶媒对照组,每组6只。
  • 右眼每12小时给予50微升滴眼液,持续35天,基线和每周评估眼部检查、角膜厚度、眼压、角膜曲率和屈光度。

主要发现

  • 基线时两组所有结局指标无显著差异,两组均出现角膜变平和远视漂移,但治疗组变化速率较慢。
  • 重复测量分析显示角膜曲率读数组间差异有统计学意义(P=0.034),治疗组角膜曲率最多陡峭0.6屈光度。
  • 停药后两组差异减小并失去统计学意义,研究期间眼压和角膜厚度无显著变化,两组均未观察到副作用。

临床怎么用

  • 结果提示角膜屈光力可能通过局部雌激素药理调控,但尚不能直接用于临床远视矫正。
  • 需进一步研究该变化的生理机制,为开发新型药物矫正屈光不正提供路径。

局限性

  • 研究为动物实验,样本量小(每组6只兔),结论外推至人类需谨慎。
  • 仅评估35天治疗期及停药后短期变化,长期效果和安全性未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In vitro studies found that 17β-estradiol (estrogen) modulates corneal biomechanical properties and reduces tissue stiffness. Therefore we hypothesized that topical estrogen might affect the refractive properties of the cornea, inducing a myopic shift. METHODS: Twelve female New Zealand white rabbits 16 weeks old were used. The rabbits were randomly divided to either the treatment group receiving 1.5% (w/v) estrogen eye drops or a control group receiving vehicle only (n = 6 each group). Both groups were given drops (50 µL) to the right eye every 12 hours for 35 days. Ocular examination, pachymetry, intraocular pressure (IOP), keratometry ,and refraction were evaluated at baseline and on a weekly basis. RESULTS: No significant differences were observed between the two groups at baseline in all outcome measures. Both groups displayed corneal flattening and a hyperopic shift. However, the change rate was slower in the treatment group. Repeated measurements analysis revealed a statistically significant difference in keratometry readings between groups (P = 0.034) with steeper keratometry by up to 0.6 diopters in the treatment group. The difference between the two groups diminished and became statistically insignificant after treatment cessation. No significant changes were observed in IOP and pachymetry throughout the study period. No side effects were observed in either group. CONCLUSIONS: Estrogen eye drops induced a myopic shift in keratometry readings. These results suggest that corneal refractive power might be manipulated pharmacologically. Further studies on the physiology behind this change are warranted to facilitate a pathway for development of novel pharmacologic treatments to correct refractive errors.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Leshno A, Prokai-Tatrai K, Rotenstreich Y, et al. Topical Estrogen Therapy for Hyperopia Correction in Vivo. Invest Ophthalmol Vis Sci. 2020. PMID: 32579682. doi:10.1167/iovs.61.6.55

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。